Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Ozempic and Wegovy Ease Knee Osteoarthritis Pain in Large Study
‘Ozempic Changed My Life’: Do Diabetes Jabs Boost the Chances of Conception?
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
‘Skinny jabs’: weight-loss drugs set for new boom as generic liraglutide versions emerge
Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020–2023
Estimated Sustainable Cost-Based Prices for Diabetes Medicines
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
Oprah Winfrey’s revelation about using weight-loss drugs is a game-changer: Here’s why
Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series
Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults with Overweight and Obesity in the US: A Real-World Evidence Study
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis
Her Insurance Refused to Pay for Wegovy, So She Sued: Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy
What Oprah Winfrey said about drugs used for weight loss like Ozempic, Mounjaro
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification
To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit Card Debts: Some people pay more than $10,000 a year out-of-pocket for Ozempic and Mounjaro
Semaglutide and cancer: A systematic review and meta-analysis
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events
Novo boosted as trial shows weight-loss Wegovy drug has [cardiovascular] medical benefits
Goodbye, Ozempic: A new class of drugs is transforming obesity care. They are not all the same
Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement
Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single-dose & multiple-ascending-dose study in healthy participants
People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For some, it’s a startling side effect
What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
I lost 40 pounds on Ozempic. But I’m left with even more questions.
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss in OASIS 1 trial
Ozempic’s Next Act: People taking the drug for weight loss say they have also stopped drinking, smoking, shopping, and even nail-biting
Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test
Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study
A New Drug Switched Off My Appetite. What’s Left? Mounjaro did what decades of struggle with managing weight couldn’t. Welcome to the post-hunger age
Why Experts Are Urging Swifter Treatment for Children With Obesity: Growing research has shown that intensive interventions are needed, scientists say. Here is why their advice is changing
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Supplement To: Dandona P, Chaudhuri A, Ghanim H. Semaglutide in Early Type 1 Diabetes
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial
Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts
Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide—Semaglutide users also more likely to experience weight loss, retrospective study suggests
Weight loss TikTok trend triggers shortage of diabetic medication
Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats
Endpoints and Estimands: Understanding Trials of Weight-Loss Drugs
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many insurance companies refuse to cover new weight loss drugs that their doctors deem medically necessary
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomized, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Wegovy™ demonstrated substantial and sustained weight loss in two-year study in adults with obesity
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4mg for weight management: a randomized, controlled, phase 1b trial
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
Once-Weekly Semaglutide in Adults with Overweight or Obesity
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder
Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
Efficacy and Safety of AM833 [cagrilintide] for Weight Loss: A Dose-finding Trial in Adults With Overweight/Obesity [abstract]
GLP-1R agonists for the treatment of obesity: a patent review (2015–present)
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats
Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
Management Of Endocrine Disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
FDA approves first oral GLP-1 treatment for type 2 diabetes
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomized, double-blind, phase 3a trial
Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents
The Discovery and Development of Liraglutide and Semaglutide
Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism
Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioral effects of drugs and alcohol: A systematic review
Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies
Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomized, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Liraglutide for psychiatric disorders: clinical evidence and challenges
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Neurobehavioral effects of liraglutide and sitagliptin in experimental models
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future
Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4
Associations of Semaglutide With First-Time Diagnosis of Alzheimer’s Disease in Patients With Type 2 Diabetes: Target Trial Emulation Using Nationwide Real-World Data in the US
Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials
Risk of Major Adverse Cardiovascular Events and All-Cause Mortality under Treatment With GLP-1 RAs or the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Overweight or Obese Adults without Diabetes: a Systematic Review and Meta-Analysis
Liraglutide Suppresses TNF-Α-Induced Degradation of Extracellular Matrix in Human Chondrocytes: a Therapeutic Implication in Osteoarthritis
Liraglutide, a Glucagon-Like Peptide 1 Receptor Agonist, Exerts Analgesic, Anti-Inflammatory and Anti-Degradative Actions in Osteoarthritis
Obesity's Relationship With Type 2 Diabetes Is Really Weird
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes
12-Month Neurological and Psychiatric Outcomes of Semaglutide Use for Type 2 Diabetes: a Propensity-Score Matched Cohort Study
It’s the Age of Ozempic. Do We Need Weight Watchers Anymore?
2024-bliddal-figure1-changeinbodyweightandarthritispainovertimeduetosemaglutide.jpg
2024-perkovic-figure1-kidneydiseasesurvivalcurvesonsemaglutidevsplacebo.jpg
2024-scirica-figure1-survivalcurveofselectsemaglutiderctforallcausemortalityduringcovid19.jpg
2023-aroda-figure3-bodyweightlossduetosemaglutide25mgand50mgdailyoraldose.jpg
2023-dandona-figure1-glycatedhemaglobininpatientswithearlytype1diabetesgivensemaglutidevshistoricalcontrols.jpg
2023-jastreboff-figure1-effectofretatrutideonweightlossover48weeks.jpg
2023-knop-figure3-oral50mgdailysemaglutidebenefitsforbmiwaistcircumferencehba1cbloodpressurecrpglycemicstatus.jpg
2023-lingvay-figure1-comparisonofmajorglp1agonistsforweightloss.jpg
2023-rosenstock-figure2-effectofretatrutideonbloodsugarbodyweightbloodpressureandlipid.jpg
2023-wharton-figure2-bodyweightlosswithdailyorforglipronglp1agonist.jpg
2022-garvey-figure2-longtermeffectsof2yearsofsemaglutideonweightloss.jpg
2022-knerr-figure2-combinedpeptideweightlosseffectsinmice.jpg
2022-wilding-figure1b-regainofbodyweightafterstoppingsemaglutide.jpg
2021-davies-figure2-bodyweightlosswithsemaglutide10mgand24mgvsplacebo.jpg
2021-enebo-figure3-cagrilintidesemaglutideweightlossovertimebydose.jpg
2021-lau-figure2-cagrilintidetotalbodyweightlossbydoseovertime.jpg
2021-muller-figure3-bodyweightlossbyantiobesitymedicationinhumansandrodents.jpg
2018-pratley-figure2-efficacyofsemaglutide05mgvsemaglutide1mgvsdulaglutide075mgatweek40insustain7rctbloodsugarweightloss.jpg
https://chadnauseam.com/random/semaglutide-has-changed-the-world/
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2774903
https://trevorklee.substack.com/p/pharmacokinetics-drug-developments#footnote-4-137517922
https://www.astralcodexten.com/p/highlights-from-the-comments-on-semaglutide
https://www.metaculus.com/questions/notebooks/8702/the-promise-and-impact-of-the-next-generation-of-weight-loss-drugs/
https://www.newyorker.com/culture/the-new-yorker-interview/jia-tolentino-on-ozempics-breakthrough-benefits-and-risky-downsides
https://www.nytimes.com/2023/05/16/well/live/ozempic-alternatives-semaglutide.html
https://www.nytimes.com/2023/11/03/well/mind/ozempic-weight-loss-antidepressants-antipsychotics.html
https://www.nytimes.com/2024/03/24/health/ozempic-wegovy-forever-drugs.html
https://www.overcomingbias.com/p/one-pill-to-break-us-allhtml
https://www.science.org/content/blog-post/missing-out-glp-1
https://www.science.org/content/blog-post/ozempic-and-other-glp-1-drugs-more-people-realize
https://www.wsj.com/health/pharma/a-weight-loss-drug-changed-my-life-will-it-solve-my-problem-aeb79260
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2024-bliddal.pdf.html
‘Skinny jabs’: weight-loss drugs set for new boom as generic liraglutide versions emerge
https%253A%252F%252Fwww.theguardian.com%252Fbusiness%252Farticle%252F2024%252Fjun%252F25%252Fskinny-jabs-weight-loss-drugs-generic-ozempic-wegovy-saxenda.html
Estimated Sustainable Cost-Based Prices for Diabetes Medicines
https%253A%252F%252Fjamanetwork.com%252Fjournals%252Fjamanetworkopen%252Ffullarticle%252F2816824.html
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
https%253A%252F%252Fwww.nature.com%252Farticles%252Fs42255-023-00943-3.html
Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2023-richards.pdf.html
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2023-lincoff.pdf.html
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2023-lingvay.pdf.html
To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit Card Debts: Some people pay more than $10,000 a year out-of-pocket for Ozempic and Mounjaro
https%253A%252F%252Fwww.wsj.com%252Fhealth%252Fhealthcare%252Fozempic-mounjaro-weight-loss-drug-cost-32fc3555.html
Novo boosted as trial shows weight-loss Wegovy drug has [cardiovascular] medical benefits
https%253A%252F%252Fwww.reuters.com%252Fbusiness%252Fhealthcare-pharmaceuticals%252Fnovos-weight-loss-drug-wegovy-cuts-risk-heart-disease-by-20-trial-data-2023-08-08%252F.html
Goodbye, Ozempic: A new class of drugs is transforming obesity care. They are not all the same
https%253A%252F%252Fwww.theatlantic.com%252Fhealth%252Farchive%252F2023%252F06%252Fozempic-pills-obesity-drugs-semaglutide%252F674541%252F.html
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2023-aroda.pdf.html
What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
https%253A%252F%252Fwww.wired.com%252Fstory%252Fobesity-drugs-researcher-interview-ozempic-wegovy%252F.html
Ozempic’s Next Act: People taking the drug for weight loss say they have also stopped drinking, smoking, shopping, and even nail-biting
https%253A%252F%252Fwww.theatlantic.com%252Fhealth%252Farchive%252F2023%252F05%252Fozempic-addictive-behavior-drinking-smoking%252F674098%252F.html
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
https%253A%252F%252Fwww.sciencedirect.com%252Fscience%252Farticle%252Fpii%252FS2212877822001028.html
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomized, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2021-lau.pdf.html
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
https%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs40262-021-01025-x.html
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4mg for weight management: a randomized, controlled, phase 1b trial
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2021-enebo.pdf.html
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2021-lundgren.pdf.html
The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders
https%253A%252F%252Fwww.sciencedirect.com%252Fscience%252Farticle%252Fpii%252FS2212877821000156.html
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2020-kushner.pdf.html
Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents
https%253A%252F%252Fwww.sciencedirect.com%252Fscience%252Farticle%252Fpii%252FS0028390819300541.html
The Discovery and Development of Liraglutide and Semaglutide
https%253A%252F%252Fwww.frontiersin.org%252Fjournals%252Fendocrinology%252Farticles%252F10.3389%252Ffendo.2019.00155%252Ffull.html
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2017-davies.pdf.html
